Get the Stockscreener App
1.57
0.00%
0.00
After Hours:
1.59
0.02
+1.27%
Caribou Biosciences Inc stock is traded at $1.57, with a volume of 1.31M.
It is up +0.00% in the last 24 hours and up +0.00% over the past month.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
See More
Previous Close:
$1.57
Open:
$1.57
24h Volume:
1.31M
Relative Volume:
0.78
Market Cap:
$168.32M
Revenue:
$11.16M
Net Income/Loss:
$-148.13M
P/E Ratio:
-0.9884
EPS:
-1.5885
Net Cash Flow:
$-112.35M
1W Performance:
-3.09%
1M Performance:
+0.00%
6M Performance:
-12.78%
1Y Performance:
-15.14%
1-Day Range:
$1.55
$1.60
1-Week Range:
$1.5194
$1.63
52-Week Range:
$1.38
$3.535
Caribou Biosciences Inc Stock (CRBU) Company Profile
Name
Caribou Biosciences Inc
Sector
Industry
Phone
510-982-6030
Address
2929 7TH STREET, SUITE 105, BERKELEY
Compare CRBU vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRBU
Caribou Biosciences Inc
|
1.57 | 172.60M | 11.16M | -148.13M | -112.35M | -1.5885 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-08-23 | Initiated | Cantor Fitzgerald | Neutral |
| Oct-31-23 | Initiated | Evercore ISI | Outperform |
| Jul-11-23 | Initiated | Truist | Buy |
| Feb-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Dec-01-21 | Initiated | Oppenheimer | Outperform |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Nov-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-17-21 | Initiated | BofA Securities | Buy |
| Aug-17-21 | Initiated | Citigroup | Neutral |
| Aug-17-21 | Initiated | SVB Leerink | Outperform |
View All
Caribou Biosciences Inc Stock (CRBU) Latest News
Caribou (CRBU) Today: Gains 3.11% to Reach $1.66 at the Close; Key Range: $1.58 and $1.74 Define the Nearby Reference Levels under the Current SnapshotVOLD Alert - vinanet.vn
Caribou Biosciences Inc (CRBU) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Caribou (CRBU) Quarterly Figures: EPS Comes in Above Forecast in the Latest Reading; Share Move - vinanet.vn
Caribou Biosciences (CRBU) Slips 1.86% to $1.58 as Gene-Editing Stock Tests Key Support LevelPut Wall - dars.gov.et
Caribou Biosciences, Inc. (NASDAQ:CRBU) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Caribou Biosciences (NASDAQ:CRBU) Price Target Cut to $5.00 by Analysts at Bank of America - MarketBeat
Citi Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Caribou Biosciences, Inc. Stock 12‑Month Price Target Cut to $11.86, Implies 636% Upside - TradingView
Caribou Biosciences earnings beat by $0.07, revenue topped estimates - Investing.com Nigeria
Caribou Biosciences (NASDAQ:CRBU) Releases Earnings Results, Beats Expectations By $0.08 EPS - MarketBeat
Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Caribou Biosciences Q2 EPS beats estimate, sales miss - scanx.trade
Form 8K Caribou Biosciences Inc For: 13 August By Investing.com - Investing.com Australia
Caribou Biosciences, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
CARIBOU BIOSCIENCES ($CRBU) Releases Q2 2026 Earnings - Quiver Quantitative
Caribou Biosciences reports Q2 2026 results: $1.5M licensing revenue, $24.3M GAAP net loss - TradingView
Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Caribou's Single-Dose CAR-T Shows 92% Response in 12 Myeloma Patients - Stock Titan
Caribou Biosciences (CRBU) Holds Near $1.70 as Gene-Editing Pipeline Remains in FocusValue Area High - vinanet.vn
CRBU Q1 2026 Earnings: Narrower-Than-Expected Loss Reflects Cost DisciplineSegment Revenue Breakdown - Vinanet
Caribou Biosciences, Inc. expected to post a loss of 32 cents a shareEarnings Preview - TradingView
Number of shareholders of Caribou Biosciences, Inc. – NASDAQ:CRBU - TradingView
Caribou Biosciences, Inc. $CRBU Stock Holdings Raised by Renaissance Technologies LLC - MarketBeat
Spotlight On Promising Penny Stocks For August 2026 - Sahm
Caribou Biosciences (CRBU) to Announce Earnings on Wednesday - MarketBeat
CRBU Q2'26 Earnings: revenue estimate is 2.28M USD - TradingView
Caribou (CRBU) Stock Analysis: Climbs +4.67%, Eyes on $1.65 2026-08-04Charm Flow - vinanet.vn
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences - TMX Newsfile
Caribou Biosciences (CRBU) Pulls Back to $1.46 as Clinical-Stage Biotech Faces Selling PressureDiagonal Spread Trade - vinanet.vn
Caribou Biosciences Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
Caribou Biosciences (CRBU) Holds Steady at $1.47 as Biotech Sector Watches Key LevelsTRIN Signal - Vinanet
BMS and Gilead rule in the CAR-T space. Off-the-shelf developers aren’t trying to change that. - Pharma Voice
Caribou Biosciences (CRBU) Falls 6% as Biotech Sentiment WeakensDynamic Hedging - vinanet.vn
CRBU|Caribou Biosciences Inc|Price:1.650|Chg%:+0.010 - TradingKey
CRBU|Caribou Biosciences Inc|Price:1.585|Chg%:+0.015 - TradingKey
Caribou Biosciences Inc (CRBU) Valuation: PE, PB & Fair Value Analysis - TradingKey
Caribou Biosciences Inc (CRBU) Cash Flow - TradingKey
BlackRock (NYSE: BLK) reports 7.2% beneficial stake in Caribou Biosciences (CRBU) - Stock Titan
Caribou Biosciences Inc (CRBU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Caribou Biosciences Inc (CRBU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Caribou Biosciences Inc (CRBU) Balance Sheet - TradingKey
Enterprise value to EBITDA forward of Caribou Biosciences, Inc. – NASDAQ:CRBU - TradingView
Caribou Biosciences Inc (CRBU) Income Statement - TradingKey
Caribou Biosciences Inc (CRBU) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Caribou Biosciences, Inc. Revenue Breakdown – NASDAQ:CRBU - TradingView
CRBU|Caribou Biosciences Inc|Price:1.550|Chg%:-0.020 - TradingKey
Caribou Biosciences Inc (CRBU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CRBU|Caribou Biosciences Inc|Price:1.570|Chg%:-0.060 - TradingKey
Caribou Biosciences Inc (CRBU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Enterprise value to EBIT forward of Caribou Biosciences, Inc. – NASDAQ:CRBU - TradingView
Price to earnings forward of Caribou Biosciences, Inc. – NASDAQ:CRBU - TradingView
Caribou Biosciences Inc Stock (CRBU) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):